This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Loser

Onyx Pharmaceuticals ( ONXX) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.6%. By the end of trading, Onyx Pharmaceuticals fell 54 cents (-0.8%) to $67.76 on light volume. Throughout the day, 1.1 million shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of two million shares. The stock ranged in price between $67.41-$68.52 after having opened the day at $68 as compared to the previous trading day's close of $68.30. Other company's within the Drugs industry that declined today were: Natural Alternatives International ( NAII), down 18.4%, StemCells ( STEM), down 17.2%, Anthera Pharmaceuticals ( ANTH), down 16.9%, and MEI Pharma ( MEIP), down 12.8%.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $4.25 billion and is part of the health care sector. The company has a P/E ratio of 60, below the average drugs industry P/E ratio of 60.6 and above the S&P 500 P/E ratio of 17.7. Shares are up 50.3% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share.

On the positive front, Somaxon Pharmaceuticals ( SOMX), up 61.5%, Supernus Pharmaceuticals ( SUPN), up 37%, ADVENTRX Pharmaceuticals ( ANX), up 19.1%, and Cormedix ( CRMD), up 17.3%, were all gainers within the drugs industry with GlaxoSmithKline ( GSK) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 17,719.00 +33.27 0.19%
S&P 500 2,052.75 +4.03 0.20%
NASDAQ 4,701.8670 +26.1550 0.56%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs